The mid-size pharmaceutical market in Europe is expected to grow from US$ 201,707.89 million in 2022 to US$ 288,168.27 million by 2028; it is estimated to grow at a CAGR of 6.1% from 2022 to 2028.
The mid-size pharmaceutical market in Europe is characterized by the presence of various market players. To increase their market share, the players adopt various strategies such as product launches, regional expansion, and technological advancements. Leading players invest in R&D to develop advanced technologies and gain revenue. Europe accounts for the second-largest market share and is anticipated to register a significant growth rate over the forecast period. The market growth in this region is attributed to the increasing number of product launches and the growing prevalence of chronic diseases. Further, increased government expenditures on the healthcare sector favor the entry of new players in the mid-size pharmaceutical market in this region. However, the cutthroat competition among market players hinders the market growth.
By introducing new features and technologies, vendors in the Europe mid-size pharmaceutical market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market growth at a good CAGR during the forecast period.
The mid-size pharmaceutical market in Europe is characterized by the presence of various market players. To increase their market share, the players adopt various strategies such as product launches, regional expansion, and technological advancements. Leading players invest in R&D to develop advanced technologies and gain revenue. Europe accounts for the second-largest market share and is anticipated to register a significant growth rate over the forecast period. The market growth in this region is attributed to the increasing number of product launches and the growing prevalence of chronic diseases. Further, increased government expenditures on the healthcare sector favor the entry of new players in the mid-size pharmaceutical market in this region. However, the cutthroat competition among market players hinders the market growth.
By introducing new features and technologies, vendors in the Europe mid-size pharmaceutical market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market growth at a good CAGR during the forecast period.
Europe Mid-Size Pharmaceutical Market Segmentation
The Europe mid-size pharmaceutical market is segmented on the basis of type, drug development type, formulation, therapy class, and country.- Based on type, the Europe mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. In 2022, the over-the-counter segment accounted for a larger market share.
- Based on drug development type, the market is bifurcated into in-house and outsource. The outsource segment held a larger market share in 2022.
- Based on formulation, the Europe mid-size pharmaceutical market is segmented into tablets and capsules, injectables, sprays, and other formulations. The tablets & capsules segment held the largest market share in 2022.
- Based on therapy class, the market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. The diabetes segment held the largest market share in 2022.
- Based on country, the Europe mid-size pharmaceutical market is segmented into Germany, France, the UK, Italy, Spain, and Rest of Europe. Germany held the largest market share in 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Mid-Size Pharmaceutical - Market Landscape
5. Mid-Size Pharmaceutical Market - Key Market Dynamics
6. Mid-Size Pharmaceutical Market- Europe Analysis
7. Europe Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028- by Type
8. Europe Mid-Size Pharmaceutical Market Analysis - By Drug Development Type
9. Europe Mid-Size Pharmaceutical Market - By Formulation
10. Europe Mid-Size Pharmaceutical Market - By Therapy Class
11. Europe Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 - Country Analysis
12. Mid-Size Pharmaceutical Market-Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
- Alexion Pharmaceuticals, Inc.
- Bausch Health Companies Inc.
- Daiichi Sankyo Company Limited
- Eisai Co., Ltd.
- Endo Pharmaceuticals Inc.
- Les Laboratories Servier
- Mallinckrodt
- Regeneron Pharmaceuticals, Inc
- Sun Pharmaceutical Industries Ltd
- UCB S.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 73 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 201707.89 Million |
| Forecasted Market Value ( USD | $ 288168.27 Million |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 10 |
![Monocyte Activation Tests Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Source, Products, and Application [Drug Development, Vaccine Development, Medical Devices, and Others] - Product Image](http://www.researchandmarkets.com/product_images/12613/12613838_60px_jpg/market_research_report.jpg)
